Details of their work are published in Nature Neuroscience in a paper titled “Laminar organization of cellular microcircuits modulating human interictal epileptiform discharges.” In it, the scientists explain that they used a high-resolution technology recently adapted for humans that records individual neuron activity to track more than 1000 neurons in four patients undergoing surgery for epilepsy. The so-called Neuropixel probes provide “a view into new ways we might address a debilitating aspect of epilepsy that we haven’t been able to tackle,” said Jon Kleen, MD, PhD, an associate professor of neurology at UCSF and co-senior author of the study. 

Preventing brain blips would be a boon for patients’ quality of life because over time, the effects of these mental disruptions can be significant and may account for some of the cognitive impairment experienced by about half of people with epilepsy. 

Neuropixels probes, which are thin devices lined with hundreds of sensors, are designed to record activity throughout the human cortex. This means that unlike current sensors which are limited to brain signals on the surface of the brain, Neuropixels can provide a three-dimensional view of brain activity. For the study, the scientists implanted the probes seven millimeters deep into the part of the brain where patients’ seizures originate—this is the tissue that surgeons typically remove to reduce epilepsy symptoms. 

Inserting the probes here made it possible to observe what happened in the neurons before, during, and after each IED. While seizures appear as a burst of neurons firing in synchrony, when IEDs occur, they unfold sequentially. Specifically, one set of neurons was active about a second before the IED started followed by another set that generated the sharp electrical spike at its peak, and then a third set became active as the IED faded. “We could see individual neurons that were just microns apart from each other playing different roles in the process,” said Alex Silva, the study’s first author and a medical student and doctoral candidate in the UCSF-UC Berkeley Joint PhD program in bioengineering. “It was really striking.”

Previous studies have demonstrated that most neurons involved in IEDs are used in normal cognitive processing. According to this study, nearly 80% of the neurons involved in IEDs were also involved in language and perception. Current implantable devices for epilepsy may be able to help. They include closed loop neurostimulators that can detect abnormal brain activity and deliver electrical pulses that interrupt it. So in the case of IEDs, devices that monitor single neurons could use the activity of the first set of neurons announcing the arrival of the abnormal pattern as a warning signal. “That would be a major step forward, changing treatment from reactively responding to abnormal brain bursts to proactively preventing them in the first place,” Kleen said.

The post Advanced Neural Probes Reveal Predictable Patterns in Epileptic Brain Activity appeared first on GEN - Genetic Engineering and Biotechnology News.

“Our findings suggest that disease-associated microbes don’t just respond to inflammation—they can actively drive it by reshaping host metabolism,” stated Wenhan Zhu, PhD, assistant professor of pathology, microbiology and immunology. “This opens up new possibilities for intervention, such as by targeting metabolic interactions between host and microbes to prevent or disrupt diseases like infectious diarrhea and colorectal cancer.

Zhu is lead corresponding author of the team’s published paper in Cell, titled “An anaerobic pathogen rewires host metabolism to fuel oxidative growth in the inflamed gut.” In their paper the team wrote, “Here, we demonstrate that ETBF leverages its virulence factor, BFT, to reprogram epithelial cell metabolism, thereby reshaping the gut nutritional landscape. This reprogramming leads to increased levels of lactate and oxygen, which fuel ETBF’s unique oxidative metabolism.”

Independent studies have implicated ETBF in both inflammatory diarrheal diseases and in colorectal cancer, the authors noted. “These pathogenic effects are primarily driven by the virulence factor Bacteroides fragilis toxin (BFT), which elicits a range of physiological alterations in host cells.” However, the team noted, “… the specific mechanisms by which BFT facilitates ETBF niche establishment and promotes persistent colonization in the gut remain largely undefined.”

Zhu has long been interested in how pathogens succeed in the competitive intestinal environment. “The gut is one of the most densely populated microbial environments in the body, with heavy competition for nutrients, yet certain microbes can still take hold and drive disease,” he said. “These microbes are ultimately competing for nutrients, and processes like inflammation and cancer may be ways they alter the environment to gain access to those resources.”

Though the percentage of people who carry ETBF varies from study to study, it can be a common member of the gut microbiota and is considered a classical anaerobe, a type of bacteria that requires low-oxygen conditions (such as those in the large intestine) to survive. It produces a toxin, BFT, that interacts with intestinal host cells, causing inflammation and increasing oxygen and oxidative stress—conditions that are usually harmful to anaerobes such as ETBF.

Zhu and colleagues are exploring how ETBF navigates and exploits these conditions, to gain insight into microbial physiology and host-microbe interactions, he said. Through their newly reported study the investigators found that ETBF uses its toxin, BFT, to reprogram intestinal epithelial cell metabolism.

The researchers discovered that ETBF reshapes the intestinal landscape in unexpected ways, for example by driving epithelial cell proliferation and manipulating immune signaling pathways and bile acid biology. “BFT manipulates colonic epithelial signaling and the bile acid recycling pathway, inducing a metabolic shift in the epithelium from oxidative phosphorylation to glycolysis,” they wrote.

This metabolic shift reduces oxygen consumption by host cells, increasing oxygen availability in the gut. The resulting environment supports the growth of ETBF, despite it being traditionally considered an anaerobe. “This shift increases local concentrations of lactate and oxygen, nutrients that support oxidative metabolism in ETBF,” they continued. These changes also create conditions that promote disease-associated microbial communities linked to colorectal cancer.

“One of our most surprising findings was that a classically anaerobic bacterium can benefit from, and even help create, an oxygen-rich environment,” Zhu said. “This challenges the traditional view that anaerobic microbes simply cannot tolerate oxygen.”

The team is continuing to explore how ETBF modifies its environment to successfully colonize and cause disease; how broadly the mechanisms apply across other microbes and disease settings; and whether these interactions can be therapeutically targeted. In their report the investigators stated, “… by sculpting an oxidative niche, ETBF both fuels its own growth and suppresses its microbial competitors. Importantly, this distinct metabolic program could potentially be leveraged to selectively target and remove ETBF.” Zhu added, “Ultimately, we hope to identify strategies to disrupt these disease-promoting niches before they lead to long-term pathology.”

The post Pathogenic Bacterium Rewires Gut Environment to Colonize and Cause Disease appeared first on GEN - Genetic Engineering and Biotechnology News.

Treatment with C-C chemokine receptor 5 (CCR5)-specific antibodies are one of a few alternative therapies for HIV infection, however dosing strategies and maintenance is challenging for both patients and manufacturers.

Researchers at Oregon Health & Science University Oregon National Primate Research Center aimed to address the need for long-term expression of CCR5-specific antibodies to establish protection from HIV using adeno-associated virus (AAV) vectors.

Their work was published in Science Translational Medicine under the title, “Adeno-associated virus gene therapy-mediated CCR5 blockade suppresses virus replication long-term in SHIV-infected macaques.”

“We explored the ability of AAV vectors expressing the CCR5-blocking antibody leronlimab to mediate a functional cure in simian-human immunodeficiency virus (SHIV)–infected rhesus macaques by interrupting viral access to the viral entry co-receptor CCR5,” wrote the authors.

Leronlimab is an antiviral HIV drug that targets and blocks the CCR5 receptor, thus blocking HIV’s ability to invade immune cells. Nineteen SHIV-infected macaques were treated with leronlimab expressing AAVs. All but one treated macaque produced detectable levels of leronlimab following AAV administration. The single animal that didn’t produce leronlimab had preexisting leronlimab-specific antidrug antibodies (ADA).

About half of the animals developed an immune response to the therapy, producing ADA clearing of leronlimab, however, over a year of observation, researchers found latent increase in stable expression of the leronlimab. Macaques that did not exhibit an immune response maintained leronlimab expression throughout the same year of observation.

Most macaques that produced sufficient number of antibodies showed long-term partial or full suppression of SHIV. “Of the nine macaques producing sufficient leronlimab to achieve full CCR5 receptor occupancy on blood CD4+ T cells, AAV-leronlimab drove stringent or partial control of SHIV viremia in six macaques long term,” wrote the authors. The three remaining macaques, when given an additional dose of leronlimab, showed either complete viral suppression or 100-fold reduction in viral load.

The authors explain that these results indicate that there is a “threshold of leronlimab expression [that] is necessary to effectively halt SHIV replication.” They also point out that while they tested multiple capsids and promotors, they were limited in assessing vector design or dose, but surmise that the AAV-leronlimab could be combined with other AAV-delivered antivirals for a multitargeted approach.

“These results demonstrate the potential of gene therapy–mediated long-term antibody-based CCR5 blockade for HIV functional cure but highlight challenges in achieving sufficient antibody expression when targeting an abundant self-antigen,” concluded the authors.

The post Long-Term SHIV Suppression Using AAV Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News.

The site is Ecolab’s first bioprocessing facility in Asia and joins an established applications network in the U.S. and U.K.

BPAL Korea supports process development from early-stage resin screening through studies designed to replicate commercial manufacturing conditions, according to Jenny Tan, vice president and general manager, Ecolab Life Sciences APAC and India. On-site scientists work alongside customers across Asia to help optimize chromatography steps, improve yield and productivity, and accelerate regulatory pathways, with the aim of reducing the need to ship resins and reference materials overseas for development work, she continues.

Asia has become one of the world’s most active biopharmaceutical manufacturing regions, with Korea, China, Japan, India, and Singapore all home to growing pipelines in biosimilars and monoclonal antibody processes that scalable downstream purification. With local technical support now in place, manufacturers across the region can shorten development cycles and maintain consistency with global operations while working to tight regulatory and cost targets, continues Tan.

“Biopharmaceutical manufacturers across Asia are under increasing pressure to scale with speed while meeting demanding regulatory and performance expectations,” she explains. “BPAL Korea strengthens our ability to work side by side with customers, bringing local expertise together with Ecolab’s global, integrated bioprocessing network.”

By combining local scientific support with Ecolab’s innovative Purolite resin portfolio, Ecolab’s new BPAL was created to help enable manufacturers to address process challenges earlier, reduce development risk, and advance programs with greater confidence as they prepare for scaleup, says Tan.

The post Bioprocessing Applications Laboratory Opened in Korea by Ecolab Life Sciences appeared first on GEN - Genetic Engineering and Biotechnology News.

Degeneration of retinal ganglion cells can cause irreversible vision loss. Pluripotent stem cells (PSCs) could, in theory, be used to replace lost ganglion cells. However, past attempts at injection of these cells have failed because the cells are not able to reach the retina.

Now, researchers have successfully demonstrated that disrupting an eye structure long suspected of blocking the growth and survival of transplanted nerve cells—the internal limiting basement membrane (ILM)—may help restore vision in people with optic nerve damage.

The work suggests that altering or removing the thin layer of tissue, which separates the light-sensing retinal tissue at the back of the eye from the gel-like vitreous fluid that fills the eye, was needed for the survival and migration of donor human PSC-derived retinal ganglion cells into the retina of mice, rats, and nonhuman primates. This technique could help transplanted retinal ganglion cells survive and grow in people with blinding optic nerve damage.

This work is published in Science Translational Medicine in the paper, “The internal limiting basement membrane inhibits functional engraftment of transplanted human retinal ganglion cells in vivo.”

Damage, or optic neuropathy, occurs when retinal ganglion cells die of disease, inflammation, or injury and stop carrying electrical signals to the brain. Common causes of damage include glaucoma, optic nerve inflammation (optic neuritis), and ischemic optic neuropathy (sudden loss of blood flow to the optic nerve).

Healthy, functional human retinal ganglion cells can be grown in a lab, but most die when transplanted, said Thomas Vincent Johnson III, MD, PhD, a professor of ophthalmology at the Johns Hopkins Wilmer Eye Institute. “Even when the retinal ganglion cells survive, they remain on the retina’s surface and do not migrate into the tissue or form the connections with other nerve cells necessary to detect light,” he noted.

Researchers have speculated that the internal limiting membrane, present in many vertebrates, including humans, may be causing transplant failures.

Starting with immunosuppressed rodents, the researchers injected lab-grown human retinal ganglion cells (hRGCs) into the vitreous humors of mice with an inborn gene mutation that caused an incomplete, patchy internal limiting membrane to form. They then injected the human retinal ganglion cells into a second group of mice treated with an enzyme solution known to partially digest the membrane without damaging the eye. Lastly, they injected a third, control group of mice treated with an inactive sterile solution. After two weeks, the team observed transplantation survival in 95% of eyes (45/50) with the inborn structural defect, 80% of enzymatically disrupted eyes (32/40), and 75% of control group eyes (12/16).

The researchers then traced where the surviving human retinal ganglion cells settled and grew in the mice, noting that a much greater percentage reached the retinal ganglion cell layer in mice born with a patchy internal limiting membrane and in those treated with the enzyme.

Capturing 3D images of the migrated cells, the researchers say they observed that 2% (plus or minus 0.6%) and 7.1% (plus or minus 1.6%) surviving cells in enzyme-treated and mutant eyes, respectively, matured to form dendrites. In contrast, migration and maturation only occurred in 0.01% plus or minus 0.01% of surviving control human retinal ganglion cells.

Conducting similar experiments in larger eyes and donated eye tissue replicated the group’s findings, establishing evidence that the inner limiting membrane is indeed a structural obstacle to neuron replacement, the researchers noted. They also established a surgical procedure for retinal ganglion cell transplantation that could be used in clinical trials, thus advancing potential methods for restoring vision in humans with optic neuropathy.

While the study’s results are promising, Johnson cautions that further work is still needed before their experimental findings can be applied to people. “We know our methods are effective, but we don’t know if completely removing the internal limiting membrane helps or harms the retinal ganglion cells in the long run,” he said. “It will likely take several years before our findings could become available as an experimental therapy, but the methods we developed will guide the field moving forward.”

The post Restoring Vision with Stem Cell–Derived Retinal Cells by Overcoming ILM Barrier appeared first on GEN - Genetic Engineering and Biotechnology News.

“Natural blood clots can be slow to form and mechanically fragile, which limits their ability to stop severe bleeding and can compromise healing,” said Jianyu Li, PhD, senior author and professor of mechanical engineering and Canada research chair in tissue repair and regeneration. “Our work shows that, when engineered appropriately, red blood cells can play a central structural role, enabling the design of stronger and more functional biomaterials.”

Senior and corresponding author Li, together with first author Shuaibing Jiang, PhD, reported on the development in Nature, in a paper titled “Engineering tough blood clots for rapid hemostasis and enhanced regeneration.” In their paper the team concluded, “Our strategy enables instantaneous clotting and markedly enhanced fracture resistance despite low structural polymer content, while preserving the intrinsic bioactivity of blood clots to enhance hemostasis and regeneration.”

Jiang, now a postdoctoral associate at Harvard Medical School, led the research during his PhD studies at McGill. Researchers at the University of British Columbia, the Medical College of Wisconsin, the University of Colorado Boulder, the University of Toronto and the research institute Versiti also contributed.

“Blood clots are pivotal for hemostasis and regeneration, but they are mechanically weak and form slowly, posing risks for life-threatening hemorrhage and limiting broader applications,” the authors wrote. “These limitations are attributed to complex coagulation cascades, abundant mechanically ineffective cells, and little structural polymers.”

Previous efforts to crosslink red blood cells (RBCs) have used chitosan, a polymer derived from crustacean shells, but these led to brittle clots, ruptured cells, and inconsistent clotting. In “click clotting,” the clot structure is fundamentally strengthened through a fast, bio-safe chemical reaction that connects proteins on the red blood cell surface, forming a solid gel in just five seconds. Because the “click” reaction doesn’t interfere with normal blood chemistry, it can work alongside the body’s natural clotting process. As a result, the artificial cell‑based gel, called a “cytogel,” can be added to whole blood, where it becomes embedded within the body’s own fibrin clot.

Li added, “The technology enables both autologous clots (using the patient’s own blood) and allogeneic clots (using type-matched donor blood). Autologous clots can be prepared in approximately 20 minutes, while allogeneic clots can be prepared within about 10 minutes. Given typical clinical time constraints, this approach has strong potential for in-patient emergency care, wound management and related settings.”

The team confirmed their results through in vitro testing, as well as through tests in rodents. “In vivo studies demonstrate that EBCs can rapidly halt hemorrhage, promote tissue regeneration, mitigate inflammation and foreign body reactions, and prevent postoperative adhesion,” the authors stated. Of particular note was effective healing and regeneration observed in the injured liver, with performance exceeding that of a clinically used product tested also tested as part of the study. “Compared with previously reported biomaterials for liver regeneration, EBC demonstrated milder inflammation and more efficient tissue regeneration,” the authors noted. Analyses showed minimal evidence of immune reactivity and no toxicity in major organs.

The researchers say that while further study is required before the cytogel can be used in clinical settings, the research establishes a foundation for its design and application.  “Overall, EBC, as a native scaffolding material, can promote tissue regeneration with minimal inflammation and foreign body responses, and prevent postoperative adhesions, outperforming the clinically used products,” the scientists concluded. “This work may motivate the development and translation of highly cellularized materials for bleeding control, wound management, tissue repair and regenerative medicine.”

“Engineered blood clots have strong potential for broad clinical use and could improve outcomes across many medical situations,” Li said.

The post “Click Clotting” Technique Rapidly Creates Stronger Blood Clots appeared first on GEN - Genetic Engineering and Biotechnology News.

Researchers at the U.S. National Institute of Standards and Technology (NIST) and EMD Millipore put forward the idea, arguing that twins could make drug distribution, which is also characterized by thousands of interactions, more resilient and efficient.

Lead author Perawit Charoenwut, a logistics researcher at NIST’s systems integration division, tells GEN, “A digital twin could be extremely helpful in all phases of the biopharmaceutical supply chain. Starting from demand planning triggered by global events such as pandemics, regional disease outbreaks, aging demographics, etc., through to being able to provide visibility on capacity requirements and limitations.”

In silico models could also provide solutions to disruption by identifying alternative supply options, such as distribution centers or regional inventories, in less time, Charoenwut says.

“Digital twins could also be helpful in evaluating different suppliers by running simulations on their potential performance, based on different demand scenarios versus their individual capacities and capabilities,” he continues.

Standards

In theory, digital twins are a good option for supply chain modeling and management. In practice, however, firms interested in the approach will need to overcome some technical challenges.

For example, one major hurdle is the lack of data standardization, according to study co-author Boonserm Kulvatunyou, PhD, a computer engineer at NIST. “Supply chain digital twins require data from across organizations and third-party sources,” he tells GEN. “The lack of industry standards creates challenges in obtaining all the necessary data.”

With this in mind, the NIST’s Industrial Ontology Foundry (IOF) is working with the National Innovation Institute for Manufacturing Biopharmaceuticals (NIIMBL) to develop open-source ontology and schema standards for connecting data.

Kulvatunyou says, “The aim is to provide a semantic foundation for connecting data and knowledge across the manufacturing and supply chain operations.

“Further work is being conducted to cover broader materials, processes, and quality data,” he says. “We would like to invite industry and academia to join this effort and benefit from these new standards.”

Industry interest

Biopharma firms interested in digital supply chains will also need to establish a solid data infrastructure, according to Charoenwut, who says companies should start small and pace themselves.

“We think that biopharma companies do believe that digital twins could make a significant difference in their supply chain efficiency and resiliency. Many of them are probably building prototypes and proofs-of-concept to demonstrate the value and potential benefits, but then soon realize the digital data foundation gaps that need to be addressed in parallel in order to fully adopt this technology.

“As digital twins can vary in detail and complexity, companies should strategize digital twin adoption by starting with lower-complexity cases based on available digital data and progressively moving up the scale to gain greater precision and new capabilities. In other words, the implementation of digital twins should be viewed as an evolution rather than a breakthrough,” he says.

The post Supply Chain Digital Twins: An Evolution, Not a Breakthrough appeared first on GEN - Genetic Engineering and Biotechnology News.

These nanoscale carriers are naturally designed for transport. They can survive digestion, move into circulation, and distribute cargo throughout the body, with studies suggesting they may even reach the brain during early development. Researchers have shown that these vesicles can influence central nervous system communication, particularly through interactions with microglia, which are crucial to the brain’s immune cells. The ability of milk exosomes to carry microRNAs and regulate epigenetic pathways, including DNA methyltransferase 1 (DNMT1), points to a sophisticated biological delivery system that the industry is now learning to harness.

That potential is especially compelling in drug manufacturing, where delivery often determines whether a therapy succeeds or fails. Traditional nanoparticles can trigger toxicity, instability, or poor absorption. Milk exosomes offer a more elegant alternative: they are biocompatible, naturally abundant, and scalable for pharmaceutical development.

Huiming Tu, MD, a researcher and clinician in the department of gastroenterology at the Affiliated Hospital of Jiangnan University in Wuxi, China, and his colleagues recently demonstrated this with ulcerative colitis. Their team developed an oral delivery platform called mEXOs@TOF, which loads the pan-JAK inhibitor tofacitinib into milk-derived exosomes. The resulting formulation showed strong pharmaceutical performance, including consistent particle size, high drug-loading efficiency, and strong stability during delivery.

More importantly, the therapy improved anti-inflammatory outcomes through multiple mechanisms. It lowered inflammatory mediators such as IL-6, IFN-γ, and nitric oxide, while increasing anti-inflammatory IL-10. It also reduced oxidative stress and suppressed activation of the JAK-STAT3 signaling pathway. In both laboratory and animal studies, the system delivered strong therapeutic benefits without detectable toxicity—an ideal benchmark for translational bioprocessing.

Cancer therapy is seeing similar innovation. Min Suk Shim, PhD, professor of nano-bioengineering at Incheon National University in the Republic of Korea, and colleagues focused on sonodynamic therapy, in which ultrasound activates a sensitizing drug to destroy tumors. Their challenge was improving intracellular delivery of chlorin e6 (Ce6), a common sonosensitizer.

The team engineered glutathione-responsive milk exosomes by incorporating a diselenide bond-bearing fatty amine derivative. This allowed the vesicles to remain stable during circulation but release Ce6 inside breast cancer cells, where glutathione concentrations are higher. Once ultrasound was applied, reactive oxygen species production increased dramatically, leading to significant cancer cell death in MCF-7 breast cancer models. The work shows how responsive bioprocess design can turn natural vesicles into precision-triggered therapeutics.

Meanwhile, scientists from Hong Kong and China have reviewed the broader landscape of milk exosomes in breast cancer treatment. Beyond acting as delivery vehicles for drugs like doxorubicin, paclitaxel, and 5-fluorouracil, milk exosomes may also have direct anti-tumor effects. They can promote apoptosis, interrupt the cell cycle, and regulate pathways such as NF-κB and STAT3. Combined with plant-derived compounds like curcumin and resveratrol, they form hybrid nanoparticles with enhanced therapeutic power.

For bioprocessing, the message is clear: milk exosomes are no longer a niche curiosity. They represent a scalable, safe, and highly adaptable platform for next-generation therapeutics—one that begins with biology’s oldest delivery system and may define medicine’s next one.

The post Milk Exosomes Transform Therapeutic Bioprocessing appeared first on GEN - Genetic Engineering and Biotechnology News.

Hagen Cramer, PhD, QurAlis’s CTO, thinks synthesizing oligonucleotides using enzymes could be more sustainable than traditional solid-phase synthesis methods, but challenges remain for the industry.

“Solid-phase synthesis is convenient—you can have everything automated, it’s fast, and can be used for [many] types of therapeutics,” he says. “However, because it’s a solid-phase synthesis, you have to wash away the external reagents with lots of solvents, and that’s why the mass intensity is high.”

By contrast, manufacturing RNA and DNA using a process that happens in nature and is aqueous-based uses fewer materials in the production of any given mass of product, notes Cramer. However, creating a wide selection of enzymes to manufacture multiple products remains a challenge for the industry.

“Enzymatic synthesis]was explored a long time ago, but it went away because people couldn’t figure out the challenges,” he points out. “But there’s now a lot more money in the industry as we have approved drugs and, hence, it’s now being reinvestigated.”

Other challenges include using enzymatic techniques for manufacturing above the 100-g scale and also speeding up these techniques to be comparable with solid-phase synthesis.

“With solid-phase synthesis, if you have a 20-mer oligonucleotide, you might have to take 80 chemical steps, and you can be efficient and complete all of that in a day, but—with an enzymatic approach—it’s going to take much longer and the development time is also large,” explains Cramer, adding that clinical-stage companies making smaller volumes may want to stick with solid-phase synthesis. But, he continues, commercial-stage companies producing large volumes of product may want to investigate enzymatic approaches as they become available.

“At a certain stage, if you’re working at commercial stage already, you can plan ahead and I think the industry will move toward these new approaches starting post-market,” he says.

The post Hopes Raised for More Sustainable Oligonucleotide Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.

The Adaptive Agent-Oriented System Control (AAOSC) framework developed by a team from the Technical University of Denmark (DTU) and SiC Systems addresses that challenge through a decentralized control layer. In it, “specialized autonomous agent ‘hives’ [are] coordinating digital twin enabled manufacturing infrastructure and real-time communications protocols.” The latter lets biomanufacturers integrate models, make learning-based inferences, and control process systems.

Four AAOSC case studies were discussed in a recent paper by Seyed Soheil Mansouri, PhD, professor at DTU and co-founder and CSO of SiC Systems and Christopher J. Savoie, PhD, co-founder and CEO of SiC Systems, and inventor of the agentic AI technology behind Siri. Those case studies “demonstrate AAOSO’s prowess [in] reducing deviating durations, averting shutdowns in severe fault scenarios, and boosting efficiency through virtual quantum and classical sensing and decentralized reasoning, all while aligning with regulatory imperatives…”

Despite its capabilities in monitoring process, identifying discrepancies, and recommending solutions, agentic AI “is not yet fully ready for complete, independent control in biopharmaceutical manufacturing,” Mansouri tells GEN. “Any AI that directly affects medicine quality still needs strong human oversight and full approval. We are getting closer, but full integration requires official [regulatory] clearance.”

The AAOSC framework that Mansouri and colleagues built may be unique in the industry. It isn’t all-knowing and “God-like,” he points out. Instead, “our methods are grounded in physics, chemistry, and biology within an agent ‘hive’—an orchestration of rule-based, mathematically informed agents. So, AAOSC is, foundationally, a different philosophy of building AI [in which] humans are in control.”

First, run in shadow mode

To introduce agentic AI, Mansouri advises starting gradually. “Run the AI alongside your current control systems in shadow mode—it watches everything and gives recommendations, but doesn’t make any actual changes without human oversight. This lets the teams learn how it works without any risks to production. Once confident, you can slowly expand its role while always keeping humans in final control.”

Both the FDA and EMA require systems that are fixed rather than continuously learning, he points out, and that can complicate adoption. To minimize the potential for regulatory issues that may arise by integrating AI into manufacturing processes, “work closely with your quality and regulatory teams from the beginning.

“Always maintain clear human responsibility, so no one is left wondering who is accountable if something goes wrong. Strong cybersecurity is essential,” Mansouri adds, “because these AI agents connect and talk to each other.” Therefore, “Start small, test thoroughly, and talk to regulators early.”

The post Adaptive, Agent-Oriented Control for Biomanufacturing Systems appeared first on GEN - Genetic Engineering and Biotechnology News.